Reproterol

Reproterol
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Inhalation (MDI), IV
ATC code	R03AC15 (WHO) ;
Legal status
Legal status	DE: § 48 AMG/§ 1 MPAV (Prescription only);
Identifiers
	IUPAC name (RS)-7-(3-{[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino}propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione;
CAS Number	54063-54-6 ;
PubChem CID	25654;
ChemSpider	23898 ;
UNII	11941YC6RN;
KEGG	D08474 ;
ChEMBL	ChEMBL1095607 ;
CompTox Dashboard (EPA)	DTXSID8023553 ;
ECHA InfoCard	100.053.579
Chemical and physical data
Formula	C18H23N5O5
Molar mass	389.412 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCCNCC(C3=CC(=CC(=C3)O)O)O;
	InChI InChI=1S/C18H23N5O5/c1-21-16-15(17(27)22(2)18(21)28)23(10-20-16)5-3-4-19-9-14(26)11-6-12(24)8-13(25)7-11/h6-8,10,14,19,24-26H,3-5,9H2,1-2H3 ; Key:WVLAAKXASPCBGT-UHFFFAOYSA-N ;
	(what is this?) (verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Reproterol is a short-acting^[1] β₂ adrenoreceptor agonist used in the treatment of asthma.^[2]

It was patented in 1965 and came into medical use in 1977.^[3]

Stereochemistry

Reproterol contains a stereocenter and is chiral. There are thus two enantiomers, the (R)-form and the (S)-form. The commercial preparations contain the drug as a racemate, an equal mixture of the two enantiomers.^[4]

Enantiomers of reproterol
(R)-Reproterol CAS number: 210710-33-1	(S)-Reproterol CAS number: 210710-34-2

References

^ Küpper T, Goebbels K, Kennes LN, Netzer NC (December 2012). "Cromoglycate, reproterol, or both--what's best for exercise-induced asthma?". Sleep & Breathing = Schlaf & Atmung. 16 (4): 1229–35. doi:10.1007/s11325-011-0638-2. PMID 22198635. S2CID 10032756.
^ Virchow JC (1999). "Reproterol: beta-2-agonist, theophylline, or both?". Respiration; International Review of Thoracic Diseases. 66 (3): 210–1. doi:10.1159/000029379. PMID 10364735. S2CID 203732706.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 54X. ISBN 9783527607495.
^ Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Vol. 57. Frankfurt/Main: Rote Liste Service GmbH. 2017. p. 196. ISBN 978-3-946057-10-9.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] Küpper T, Goebbels K, Kennes LN, Netzer NC (December 2012). "Cromoglycate, reproterol, or both--what's best for exercise-induced asthma?". Sleep & Breathing = Schlaf & Atmung. 16 (4): 1229–35. doi:10.1007/s11325-011-0638-2. PMID 22198635. S2CID 10032756.

[pmid10364735-2] Virchow JC (1999). "Reproterol: beta-2-agonist, theophylline, or both?". Respiration; International Review of Thoracic Diseases. 66 (3): 210–1. doi:10.1159/000029379. PMID 10364735. S2CID 203732706.

[Fis2006-3] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 54X. ISBN 9783527607495.

[Rote_Liste-4] Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Vol. 57. Frankfurt/Main: Rote Liste Service GmbH. 2017. p. 196. ISBN 978-3-946057-10-9.

[1]

[2]

[3]

[4]